Drug Profile

CLBS 119

Alternative Names: CLBS-119

Latest Information Update: 28 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Caladrius Biosciences
Developer Lisata Therapeutics
Class Cell therapies; Haematopoietic stem cells therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Lung disorders

Most Recent Events

28 Nov 2023 No recent reports of development identified for phase-I development in Lung-disorders in USA (Parenteral)
14 Sep 2022 Cend Therapeutics has merged with Caladrius Biosciences to form Lisata Therapeutics
14 Dec 2020 Caladrius Biosciences suspends a pilot phase I trial in Lung disorders (In patients with COVID-19 infections) due to characterization of the COVID-19 patient suffering long-term effects continues to evolve

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com